Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 7 | 2024 | 260 | 1.710 |
Why?
|
| Pulmonary Fibrosis | 8 | 2023 | 137 | 1.460 |
Why?
|
| Lung Transplantation | 4 | 2023 | 290 | 1.430 |
Why?
|
| Alveolar Epithelial Cells | 4 | 2020 | 18 | 1.030 |
Why?
|
| DNA, Mitochondrial | 6 | 2021 | 187 | 1.020 |
Why?
|
| Sirtuin 3 | 3 | 2021 | 30 | 0.790 |
Why?
|
| Tissue and Organ Procurement | 2 | 2023 | 345 | 0.760 |
Why?
|
| Myositis | 1 | 2020 | 18 | 0.700 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 52 | 0.620 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 4 | 2024 | 196 | 0.570 |
Why?
|
| Apoptosis | 4 | 2020 | 1716 | 0.560 |
Why?
|
| Patient Selection | 1 | 2018 | 682 | 0.490 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 352 | 0.480 |
Why?
|
| DNA Damage | 5 | 2021 | 371 | 0.480 |
Why?
|
| Asbestos | 5 | 2021 | 22 | 0.460 |
Why?
|
| Mitochondria | 5 | 2021 | 553 | 0.440 |
Why?
|
| Waiting Lists | 2 | 2023 | 183 | 0.370 |
Why?
|
| Oxidants | 2 | 2017 | 86 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2657 | 0.250 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2024 | 42 | 0.230 |
Why?
|
| Transplant Recipients | 2 | 2023 | 137 | 0.230 |
Why?
|
| Bleomycin | 3 | 2020 | 102 | 0.220 |
Why?
|
| Emphysema | 1 | 2023 | 23 | 0.220 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 35 | 0.220 |
Why?
|
| Monocytes | 2 | 2021 | 218 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 35 | 0.210 |
Why?
|
| DNA Glycosylases | 2 | 2020 | 25 | 0.210 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 25 | 0.200 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 22 | 0.200 |
Why?
|
| Frailty | 1 | 2023 | 76 | 0.200 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 20 | 0.200 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 31 | 0.190 |
Why?
|
| Occupational Health | 1 | 2021 | 36 | 0.180 |
Why?
|
| Lung | 3 | 2024 | 1258 | 0.180 |
Why?
|
| Asbestosis | 1 | 2020 | 5 | 0.180 |
Why?
|
| Registries | 2 | 2021 | 778 | 0.180 |
Why?
|
| Humans | 17 | 2024 | 89063 | 0.180 |
Why?
|
| Catalase | 2 | 2017 | 49 | 0.180 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2020 | 18 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 169 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 87 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2023 | 490 | 0.170 |
Why?
|
| Gene Expression | 2 | 2021 | 1310 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2020 | 213 | 0.160 |
Why?
|
| Glucuronidase | 1 | 2017 | 23 | 0.150 |
Why?
|
| A549 Cells | 1 | 2017 | 41 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 71 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 116 | 0.140 |
Why?
|
| Mice | 6 | 2021 | 11737 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 127 | 0.130 |
Why?
|
| Aging | 2 | 2017 | 716 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2016 | 688 | 0.100 |
Why?
|
| Male | 10 | 2024 | 42251 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1990 | 0.100 |
Why?
|
| Animals | 7 | 2021 | 27317 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1574 | 0.100 |
Why?
|
| Oxidative Stress | 3 | 2021 | 458 | 0.090 |
Why?
|
| Female | 9 | 2024 | 46011 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2023 | 4273 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 9003 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 1715 | 0.080 |
Why?
|
| Salicylates | 2 | 2017 | 25 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2024 | 2863 | 0.070 |
Why?
|
| Middle Aged | 5 | 2024 | 25863 | 0.070 |
Why?
|
| Organometallic Compounds | 2 | 2017 | 134 | 0.070 |
Why?
|
| Aged | 4 | 2024 | 19077 | 0.070 |
Why?
|
| United States | 3 | 2024 | 6955 | 0.060 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 1975 | 0.060 |
Why?
|
| Prognosis | 2 | 2024 | 3773 | 0.060 |
Why?
|
| Biomarkers | 2 | 2021 | 1755 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 29 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 490 | 0.050 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5320 | 0.050 |
Why?
|
| North America | 1 | 2023 | 184 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 208 | 0.050 |
Why?
|
| Telomere | 1 | 2023 | 114 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 204 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 144 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2362 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 848 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 570 | 0.050 |
Why?
|
| Titanium | 1 | 2020 | 20 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 9 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 76 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 2014 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 57 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 159 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 234 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 557 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 3373 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1889 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 16 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 45 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1043 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1488 | 0.040 |
Why?
|
| Protective Agents | 1 | 2017 | 33 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2016 | 3 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1796 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2476 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 571 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 162 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 190 | 0.030 |
Why?
|
| Transgenes | 1 | 2016 | 185 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1875 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 181 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 340 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 148 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2752 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2612 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 293 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1662 | 0.030 |
Why?
|
| Guanine | 1 | 2015 | 207 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3657 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2290 | 0.030 |
Why?
|
| DNA Repair | 1 | 2015 | 362 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 646 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3209 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 26507 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 2495 | 0.030 |
Why?
|
| Child | 1 | 2023 | 7149 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5466 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2011 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 2347 | 0.010 |
Why?
|